<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02717494</url>
  </required_header>
  <id_info>
    <org_study_id>NICHD P1091</org_study_id>
    <nct_id>NCT02717494</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of Anti-Pneumococcal Vaccines in HIV-Infected Pregnant Women</brief_title>
  <official_title>Safety and Immunogenicity of Anti-Pneumococcal Vaccines in HIV-Infected Pregnant Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Westat</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Westat</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to determine the safety, reactogenicity, immunogenicity,
      transplacental antibody transfer and interference with infant responses to childhood
      vaccination of maternal vaccination with pneumococcal conjugate 10-valent vaccine (PCV-10) or
      pneumococcal polysaccharide 23-valent vaccine (PPV-23) by comparison with placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a multi-center, Phase II, randomized, double-blinded, placebo-controlled study of
      Human Immunodeficiency Virus (HIV)-infected pregnant women on Highly Active Antiretroviral
      Therapy (HAART) who were in the second or third trimester of pregnancy and of their infants.
      The study was designed to investigate the safety, reactogenicity, immunogenicity,
      transplacental antibody transfer and interference with infant responses to childhood
      vaccination of maternal vaccination with PCV-10 or PPV-23 by comparison with placebo.

      Mothers were randomized to one of three arms and received PCV-10, PPV-23, or placebo in a
      blinded fashion. They were followed for safety, immunogenicity and vaccine-specific
      anti-capsular pneumococcus (PNC) antibody persistence until 24 weeks post-delivery. Women who
      received placebo were randomized to a second study step and received PCV-10 or PPV-23 at 24
      weeks post-delivery. Antibody responses to the vaccine administered 6 months postpartum were
      measured. Women who received placebo but cannot be randomized to a second study step due to
      ongoing new pregnancy were enrolled in a third study step and receive open label PCV-10 at
      the last study visit; no data were collected on these women and they were not followed after
      vaccine administration. All infants received PCV-10 vaccinations per local standard of care.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">May 2019</completion_date>
  <primary_completion_date type="Actual">November 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Women Who Experienced Various Adverse Events (AEs)</measure>
    <time_frame>up to 24 Weeks Post-Delivery for mother participants.</time_frame>
    <description>The number of women who experienced grade ≥ 3 adverse events (AEs) in the 4 weeks after vaccination in Step 1 and grade 4 AEs or death up to 24 weeks post-partum. AE grading (Grade 1- mild to Grade 4-life-threatening) was done by DAIDS AE Grading table v2.0 (see References).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Women Who Experienced Grade ≥ 3 Adverse Events (AEs) in Step 2</measure>
    <time_frame>up to 4 Weeks after Step 2 vaccination for Mother Participants</time_frame>
    <description>The number of women who enrolled in Step 2, received vaccine and who experience grade ≥ 3 adverse events (AEs) in the 4 weeks after vaccination in Step 2 is presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Infants With Various Adverse Events Following Maternal Vaccination With PCV10 and PPV23 Administered in Pregnancy</measure>
    <time_frame>through 24 weeks of life for infant participants</time_frame>
    <description>The number of infants who experience grade ≥ 3 adverse events (AEs), congenital defects, HIV infections or pneumonia, meningitis or IPD after maternal vaccination in Step 1, assessed from birth through 24 weeks of life for infant participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Women With a Two-fold or Higher Increase in ELISA-measured IgG PNC Antibody Concentrations</measure>
    <time_frame>28 days after Immunization in Step 1</time_frame>
    <description>The number of participants with a two-fold or higher increase in ELISA-measured IgG PNC antibody concentrations from baseline to 28 days after immunization in Step 1 to 1 or more serotypes.
The proportion of participants with &gt;=0.35ug/mL ELISA-measured IgG PNC antibody concentrations at 28 days after immunization in Step 1 to 1 or more serotypes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Infant Participants With ELISA-measured IgG PNC Antibody Levels ≥ 0.35ug/mL at 8 Weeks of Age</measure>
    <time_frame>8 Weeks of Life</time_frame>
    <description>The number of infant participants with ELISA-measured IgG PNC antibody levels ≥ 0.35ug/mL at 8 weeks of age to 1 or more serotypes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ratio of Infant/Mother PNC Antibody Levels</measure>
    <time_frame>At Delivery for Mother Participants and Birth for Infant Participants</time_frame>
    <description>The ratios of infant/mother PNC antibody levels to study used serotypes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a &gt;=0.35ug/mL ELISA-measured IgG PNC Antibody Concentrations at Labor/Delivery and 24 Weeks Post-partum</measure>
    <time_frame>at Labor and Delivery and 24 Weeks Post-Delivery for Mother Participants</time_frame>
    <description>The number of participants with a &gt;=0.35ug/mL ELISA-measured IgG PNC antibody concentrations at the time points listed for 1 or more serotypes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Two-fold or Higher Increase in ELISA-measured IgG PNC Antibody Concentrations at 28 Days After PPV-23 Vaccination in Step 1 and Step 2</measure>
    <time_frame>28 days after Immunization in Step 1 and in Step 2</time_frame>
    <description>The number of participants with a two-fold or higher increase in ELISA-measured IgG PNC antibody concentrations from baseline to 28 days after immunization in Step 1 vs from entry to Step 2 to 28 days after immunization in Step 2 to 1 or more serotypes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Two-fold or Higher Increase in ELISA-measured IgG PNC Antibody Concentrations at 28 Days After PCV-10 Vaccination in Step 1 and Step 2</measure>
    <time_frame>28 days after Immunization in Step 1 and in Step 2</time_frame>
    <description>The proportion of participants with a two-fold or higher increase in ELISA-measured IgG PNC antibody concentrations from baseline to 28 days after immunization in Step 1 vs from entry to Step 2 to 28 days after immunization in Step 2 to 1 or more serotypes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Infant Participants With ELISA-measured IgG PNC Antibody Levels ≥ 0.35ug/mL at 16 and 24 Weeks of Age</measure>
    <time_frame>at weeks 16 and 24 of life</time_frame>
    <description>The number of infant participants with ELISA-measured IgG PNC antibody levels ≥ 0.35ug/mL at 16 and 24 weeks of age to 1 or more serotypes.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">347</enrollment>
  <condition>PNC Vaccine</condition>
  <condition>HIV-infected Pregnant Women</condition>
  <arm_group>
    <arm_group_label>Arm 1A (PPV-23)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Step 1, women in Arm 1A were administered a 0.5 milliliter (mL) dose of PPV-23 intramuscularly once.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 1B (PCV-10)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Step 1, women in Arm 1B were administered a 0.5 mL dose of PCV-10 intramuscularly once.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 1C (placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In Step 1, women in Arm 1C were administered a 0.5 mL dose of 0.9 percent Sodium Chloride (NaCl) intramuscularly once.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2A (PPV-23)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Step 2, women who received placebo in step 1 that were randomized to Arm 2A were administered a 0.5 mL dose of PPV-23 intramuscularly once.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2B (PCV-10)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Step 2, women who received placebo in step 1 that were randomized to Arm 2B were administered a 0.5 mL dose of PCV-10 intramuscularly once.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Step 3 (PCV-10)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Step 3, women who received placebo in step 1 and failed entry into step 2 due to ongoing new pregnancy were administered a 0.5 mL dose of PCV-10 intramuscularly once.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PPV-23</intervention_name>
    <description>PPV-23 was a polysaccharide PNC vaccine, licensed in Brazil, directed against 23 serotypes.</description>
    <arm_group_label>Arm 1A (PPV-23)</arm_group_label>
    <arm_group_label>Arm 2A (PPV-23)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PCV-10</intervention_name>
    <description>PCV-10 was a conjugate PNC vaccine, licensed in Brazil, directed against 10 serotypes.</description>
    <arm_group_label>Arm 1B (PCV-10)</arm_group_label>
    <arm_group_label>Arm 2B (PCV-10)</arm_group_label>
    <arm_group_label>Step 3 (PCV-10)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>NaCl</intervention_name>
    <description>NaCl was the placebo for the study against which the two vaccines were compared during pregnancy.</description>
    <arm_group_label>Arm 1C (placebo)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Step 1 Inclusion Criteria for Pregnant Women:

          1. Pregnant women ≥ 18 years old who provided written informed consent prior to study
             initiation.

          2. Pregnant women &lt; 18 years old with parent or legal guardian able and willing to
             provide signed informed consent, or who had the capacity to consent for themselves, as
             defined by the local Institutional Review Board (IRB), and who provided written
             informed consent prior to study initiation.

          3. Gestational age [≥ 14 weeks (14 weeks 0 days) to &lt; 33 weeks (32 weeks 6 days)]
             documented by the approximate date of the last menstrual period and corroborated by
             ultrasound if obtained as per local standard of care. Results of the ultrasound were
             recorded on the Abdominal Ultrasound Form.

          4. Documentation of HIV-1 infection defined as positive results from two samples
             collected at different time points as per standard of care. Results and source
             documentation may have been obtained from the medical records.

          5. Receipt of HAART (a regimen of at least three ARV drugs) for ≥ 4 weeks prior to
             enrollment.

          6. Documented platelet count of &gt; 50,000/mm3 and an absolute neutrophil count (ANC) of &gt;
             500/ mm3 ≤ 28 days prior to study entry.

          7. Women who were willing and able to comply with the study visits.

        Step 1 Exclusion Criteria for Pregnant Women:

          1. Receipt of any PCV or PPV-23 at any time prior to enrollment, documented by medical
             history or record.

          2. Receipt of any live licensed vaccine ≤ 4 weeks or inactivated licensed vaccine ≤ 2
             weeks prior to study entry.

          3. Receipt of a non-licensed agent (vaccine, drug, biologic, device, blood product, or
             medication) ≤ 4 weeks prior to enrollment in this study, or expectations to receive
             another non-licensed agent before delivery unless approval from the protocol team is
             obtained.

          4. Any significant (in the opinion of the site investigator) acute illness and/or oral
             temperature greater than or equal to 100.4 degrees F ≤ 24 hours prior to study entry.

          5. Women who planed to terminate their pregnancy.

          6. Women who had a prior history of lupus or other autoimmune disorders.

          7. Use of anti-cancer systemic chemotherapy or radiation therapy ≤ 48 weeks of study
             enrollment, or evidence of immunosuppression as a result of an underlying illness
             (other than HIV-1 infection) or treatment.

          8. Ongoing neoplastic disease (excluding non-melanoma skin cancer, and human papilloma
             virus-related cervical dysplasia, cervical intraepithelial neoplasia (CIN) grades 1, 2
             or 3).

          9. Long term use of glucocorticoids, including oral or parenteral prednisone ≥ 20 mg/day
             or equivalent for more than 2 consecutive weeks (or 2 weeks total) within 12 weeks of
             study entry.

         10. Women who received last dose of corticosteroids for preterm labor ≤ 1 week prior to
             study entry. Note: A woman can be enrolled if more than 1 week has elapsed from the
             last dose of corticosteroids, i.e., enrollment may be delayed to satisfy this
             criterion.

         11. Receipt of immunoglobulin or other blood products (with exception of Rho D immune
             globulin) ≤ 12 weeks prior to enrollment in this study or is scheduled to receive
             immunoglobulin or other blood products (with the exception of Rho D immune globulin)
             during pregnancy or for the first 24 weeks after delivery.

         12. Receipt of Interleukin-2 (IL2), interferon (IFN), granulocyte-macrophage
             colony-stimulating factor (GMCSF) or other immune mediators ≤ 12 weeks before
             enrollment.

         13. History of a severe adverse reaction to inactivated polysaccharide or conjugated
             vaccines.

         14. Any condition that would, in the opinion of the site investigator, place the
             participant at an unacceptable risk of injury or render the participant unable to meet
             the requirements of the protocol.

         15. Pregnancy complications (in the current pregnancy) such as pre-term labor, and
             pre-eclampsia or any other pregnancy related complication, which in the opinion of the
             investigator might jeopardize the results of the study.

         16. Chronic hepatitis B infection that may require administration of Hepatitis B
             Hyperimmune Globulin to neonates.

        Step 2 Inclusion Criteria for Women:

          1. 24 weeks ± 4 weeks postpartum.

          2. Completion of Step 1.

          3. Receipt of placebo on Step 1.

        Step 2 Exclusion Criteria for Women:

          1. Pregnancy.

          2. Receipt of any live licensed vaccine ≤ 4 weeks or inactivated licensed vaccine ≤ 2
             weeks prior to Step 2 entry.

          3. Receipt of a non-licensed agent (vaccine, drug, biologic, device, blood product, or
             medication) ≤ 4 weeks prior to vaccination, or expects to receive another non-licensed
             agent within 28 days after vaccination.

          4. Any significant (in the opinion of the site investigator) acute illness and/or oral
             temperature greater than or equal to 100.4 degrees F within 24 hours of entry except
             when, in the opinion of the physician, withholding the agent entails even greater
             risk.

          5. Use of anti-cancer systemic chemotherapy or radiation therapy or has developed
             immunosuppression as a result of an underlying illness (other than HIV-1 infection) or
             treatment.

          6. Use of glucocorticoids, including oral or parenteral prednisone ≥ 20 mg/day or
             equivalent for more than 2 consecutive weeks (or 2 weeks total) within 2 weeks of
             entry in Step 2.

          7. Receipt of immunoglobulin or other blood products (with exception of Rho D immune
             globulin) within 12 weeks prior to entry in Step 2 or is scheduled to receive
             immunoglobulin or other blood products (with the exception of Rho D immune globulin)
             during the 28 days following vaccination.

          8. Receipt of IL2, IFN, GMCSF or other immune mediators ≤ 12 weeks before entry in Step
             2.

        Step 3 Inclusion Criteria for Women

          1. 24 weeks ± 4 weeks postpartum.

          2. Completion of Step 1.

          3. Receipt of placebo on Step 1.

          4. Met Step 2 exclusion criterion of pregnancy.

        Step 3 Exclusion Criteria for Women

        None.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adriana Weinberg, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marisa Mussi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Sao Paulo Ribeirão Preto School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Geraldo Duarte, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Sao Paulo Ribeirão Preto School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>FUNDEP (Belo Horizonte)</name>
      <address>
        <city>Belo Horizonte</city>
        <state>Minas Gerais</state>
        <zip>30130-100</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Geral de Nova Iguaçu Avenida Henrique Duque Estrada Mayer</name>
      <address>
        <city>Nova Iguaçu</city>
        <state>Rio De Janeiro</state>
        <zip>26030-380</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital dos Servidores (Rio de Janeiro)</name>
      <address>
        <city>Saude</city>
        <state>Rio De Janeiro</state>
        <zip>20221-161</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Puericultura e Pediatria Martagao Gesteria</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>21 940 590</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universidade de Caxias do Sul. Brasil</name>
      <address>
        <city>Caxias do Sul</city>
        <state>RS</state>
        <zip>95070-560</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Casa Porto Alegre Brazil</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90020-090</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Nossa Senhora da Conceicao</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>91350-200</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ribeirão Preto Medical School, University of São Paulo, Brazil</name>
      <address>
        <city>Ribeirao Preto</city>
        <state>Sao Paulo</state>
        <zip>14049-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <link>
    <url>https://www.nichdclinicalstudies.org/</url>
    <description>NICHD website</description>
  </link>
  <link>
    <url>https://rsc.niaid.nih.gov/clinical-research-sites/daids-adverse-event-grading-tables</url>
    <description>The Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events</description>
  </link>
  <link>
    <url>https://rsc.niaid.nih.gov/clinical-research-sites/manual-expedited-reporting-adverse-events-daids</url>
    <description>Manual for Expedited Reporting of Adverse Events to DAIDS (DAIDS EAE Manual), Version 2.0, January 2010</description>
  </link>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>March 18, 2016</study_first_submitted>
  <study_first_submitted_qc>March 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2016</study_first_posted>
  <results_first_submitted>November 6, 2019</results_first_submitted>
  <results_first_submitted_qc>December 31, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 18, 2020</results_first_posted>
  <last_update_submitted>December 31, 2019</last_update_submitted>
  <last_update_submitted_qc>December 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PPV-23</keyword>
  <keyword>PCV-10</keyword>
  <keyword>HIV</keyword>
  <keyword>Immunization</keyword>
  <keyword>Pregnancy</keyword>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 28, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/94/NCT02717494/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 23, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/94/NCT02717494/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period was from April 2016 to November 2017. Participants were recruited from medical clinics.</recruitment_details>
      <pre_assignment_details>Of the 347 pregnant women enrolled in the study, 346 were randomized and received study vaccination. One discontinued study prior to receiving study vaccination.
There were 349 infants born on the study, including 4 sets of twins. Two women discontinued study prior to delivering their child. Those children are not included in the outcome results.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm 1A (PPV-23)</title>
          <description>In Step 1, women in Arm 1A were administered a 0.5 milliliter (mL) dose of PPV-23 intramuscularly once.
PPV-23: PPV-23 was a polysaccharide PNC vaccine, licensed in Brazil, directed against 23 serotypes.</description>
        </group>
        <group group_id="P2">
          <title>Arm 1B (PCV-10)</title>
          <description>In Step 1, women in Arm 1B were administered a 0.5 mL dose of PCV-10 intramuscularly once.
PCV-10: PCV-10 was a conjugate PNC vaccine, licensed in Brazil, directed against 10 serotypes.</description>
        </group>
        <group group_id="P3">
          <title>Arm 1C (Placebo)</title>
          <description>In Step 1, women in Arm 1C were administered a 0.5 mL dose of 0.9 percent Sodium Chloride (NaCl) intramuscularly once.
NaCl: NaCl was the placebo for the study against which the two vaccines were compared during pregnancy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention (Step 1)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="115"/>
                <participants group_id="P2" count="115"/>
                <participants group_id="P3" count="116"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Were Randomized to Step 2A (PPV-23)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Were Randomized to Step 2B (PCV-10)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Were Enrolled in Step 3 (PCV-10)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="109"/>
                <participants group_id="P2" count="108"/>
                <participants group_id="P3" count="111"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Intervention (Step 2 or Step 3)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">Only Step 1 placebo recipients were enrolled in Step 2.</participants>
                <participants group_id="P2" count="0">Only Step 1 placebo recipients were enrolled in Step 2.</participants>
                <participants group_id="P3" count="110">One participant who completed Step 1 did not enroll in Step 2.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Step 2A</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Step 2B</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Step 3</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="106"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Mother participants who received study treatment in Step 1 were included.</population>
      <group_list>
        <group group_id="B1">
          <title>Arm 1A (PPV-23)</title>
          <description>In Step 1, women in Arm 1A were administered a 0.5 milliliter (mL) dose of PPV-23 intramuscularly once.
PPV-23: PPV-23 was a polysaccharide PNC vaccine, licensed in Brazil, directed against 23 serotypes.</description>
        </group>
        <group group_id="B2">
          <title>Arm 1B (PCV-10)</title>
          <description>In Step 1, women in Arm 1B were administered a 0.5 mL dose of PCV-10 intramuscularly once.
PCV-10: PCV-10 was a conjugate PNC vaccine, licensed in Brazil, directed against 10 serotypes.</description>
        </group>
        <group group_id="B3">
          <title>Arm 1C (Placebo)</title>
          <description>In Step 1, women in Arm 1C were administered a 0.5 mL dose of 0.9 percent Sodium Chloride (NaCl) intramuscularly once.
NaCl: NaCl was the placebo for the study against which the two vaccines were compared during pregnancy.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="115"/>
            <count group_id="B2" value="115"/>
            <count group_id="B3" value="116"/>
            <count group_id="B4" value="346"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>This is age at randomization, in years.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28" spread="6"/>
                    <measurement group_id="B2" value="27" spread="6"/>
                    <measurement group_id="B3" value="28" spread="6"/>
                    <measurement group_id="B4" value="28" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="115"/>
                    <measurement group_id="B2" value="115"/>
                    <measurement group_id="B3" value="116"/>
                    <measurement group_id="B4" value="346"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="110"/>
                    <measurement group_id="B2" value="112"/>
                    <measurement group_id="B3" value="113"/>
                    <measurement group_id="B4" value="335"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="61"/>
                    <measurement group_id="B4" value="169"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="68"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="104"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="115"/>
                    <measurement group_id="B2" value="115"/>
                    <measurement group_id="B3" value="116"/>
                    <measurement group_id="B4" value="346"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gestational Age at Randomization</title>
          <description>This is the estimated gestational age at study randomization, in weeks.</description>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25" spread="5"/>
                    <measurement group_id="B2" value="25" spread="5"/>
                    <measurement group_id="B3" value="26" spread="5"/>
                    <measurement group_id="B4" value="26" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CD4% at Randomization</title>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32" spread="9"/>
                    <measurement group_id="B2" value="32" spread="9"/>
                    <measurement group_id="B3" value="31" spread="9"/>
                    <measurement group_id="B4" value="32" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CD4 Count at Randomization</title>
          <units>cells/microliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="585" spread="257"/>
                    <measurement group_id="B2" value="596" spread="243"/>
                    <measurement group_id="B3" value="564" spread="297"/>
                    <measurement group_id="B4" value="582" spread="266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>RNA Copies at Randomization</title>
          <units>copies/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="569" spread="1825"/>
                    <measurement group_id="B2" value="307" spread="1278"/>
                    <measurement group_id="B3" value="1144" spread="7864"/>
                    <measurement group_id="B4" value="674" spread="4730"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Log10 RNA Copies at Randomization</title>
          <units>log10(copies)/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.9" spread="0.6"/>
                    <measurement group_id="B2" value="1.9" spread="0.5"/>
                    <measurement group_id="B3" value="1.8" spread="0.6"/>
                    <measurement group_id="B4" value="1.9" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Women Who Experienced Various Adverse Events (AEs)</title>
        <description>The number of women who experienced grade ≥ 3 adverse events (AEs) in the 4 weeks after vaccination in Step 1 and grade 4 AEs or death up to 24 weeks post-partum. AE grading (Grade 1- mild to Grade 4-life-threatening) was done by DAIDS AE Grading table v2.0 (see References).</description>
        <time_frame>up to 24 Weeks Post-Delivery for mother participants.</time_frame>
        <population>All women randomized to vaccine or placebo, and who received the study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1A (PPV-23)</title>
            <description>In Step 1, women in Arm 1A were administered a 0.5 milliliter (mL) dose of PPV-23 intramuscularly once.
PPV-23: PPV-23 was a polysaccharide PNC vaccine, licensed in Brazil, directed against 23 serotypes.</description>
          </group>
          <group group_id="O2">
            <title>Arm 1B (PCV-10)</title>
            <description>In Step 1, women in Arm 1B were administered a 0.5 mL dose of PCV-10 intramuscularly once.
PCV-10: PCV-10 was a conjugate PNC vaccine, licensed in Brazil, directed against 10 serotypes.</description>
          </group>
          <group group_id="O3">
            <title>Arm 1C (Placebo)</title>
            <description>In Step 1, women in Arm 1C were administered a 0.5 mL dose of 0.9 percent Sodium Chloride (NaCl) intramuscularly once.
NaCl: NaCl was the placebo for the study against which the two vaccines were compared during pregnancy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Women Who Experienced Various Adverse Events (AEs)</title>
          <description>The number of women who experienced grade ≥ 3 adverse events (AEs) in the 4 weeks after vaccination in Step 1 and grade 4 AEs or death up to 24 weeks post-partum. AE grading (Grade 1- mild to Grade 4-life-threatening) was done by DAIDS AE Grading table v2.0 (see References).</description>
          <population>All women randomized to vaccine or placebo, and who received the study treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="115"/>
                <count group_id="O3" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 3+ AEs, up to week 4, Step 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4+ AEs, after week 4, Step 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3+ AEs related to treatment, Step 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>% with grade 3+ AEs, up to week 4 Step 1</param_type>
            <param_value>2</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0</ci_lower_limit>
            <ci_upper_limit>5</ci_upper_limit>
            <estimate_desc>Confidence intervals were Exact Clopper-Pearson.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>% with grade 3+ AEs, up to week 4 Step 1</param_type>
            <param_value>3</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1</ci_lower_limit>
            <ci_upper_limit>7</ci_upper_limit>
            <estimate_desc>Confidence intervals were Exact Clopper-Pearson.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>% with grade 3+ AEs up to week 4, Step 1</param_type>
            <param_value>3</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1</ci_lower_limit>
            <ci_upper_limit>8</ci_upper_limit>
            <estimate_desc>Confidence intervals were Exact Clopper-Pearson.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>% with grade 4+ AEs after week 4, Step 1</param_type>
            <param_value>1</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0</ci_lower_limit>
            <ci_upper_limit>4</ci_upper_limit>
            <estimate_desc>Confidence intervals were Exact Clopper-Pearson.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>% with grade 4+ AEs after week 4, Step 1</param_type>
            <param_value>2</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0</ci_lower_limit>
            <ci_upper_limit>5</ci_upper_limit>
            <other_analysis_desc>Confidence intervals were Exact Clopper-Pearson.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>% with grade 4+ AEs, after week 4 Step 1</param_type>
            <param_value>3</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1</ci_lower_limit>
            <ci_upper_limit>8</ci_upper_limit>
            <estimate_desc>Confidence intervals were Exact Clopper-Pearson.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>% with Grade 3+ related to treatment</param_type>
            <param_value>1</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0</ci_lower_limit>
            <ci_upper_limit>4</ci_upper_limit>
            <estimate_desc>Confidence intervals were Exact Clopper-Pearson.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>% with Grade 3+ related to treatment</param_type>
            <param_value>1</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0</ci_lower_limit>
            <ci_upper_limit>4</ci_upper_limit>
            <estimate_desc>Confidence intervals were Exact Clopper-Pearson.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>% with Grade 3+ related to treatment</param_type>
            <param_value>1</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0</ci_lower_limit>
            <ci_upper_limit>4</ci_upper_limit>
            <estimate_desc>Confidence intervals were Exact Clopper-Pearson.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Women Who Experienced Grade ≥ 3 Adverse Events (AEs) in Step 2</title>
        <description>The number of women who enrolled in Step 2, received vaccine and who experience grade ≥ 3 adverse events (AEs) in the 4 weeks after vaccination in Step 2 is presented.</description>
        <time_frame>up to 4 Weeks after Step 2 vaccination for Mother Participants</time_frame>
        <population>Women who received Placebo in Step 1 and who were eligible and were randomized to Step 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 2A (PPV-23)</title>
            <description>In Step 2, women who received Placebo in Step 1 and who were randomized to Arm 2A were administered a 0.5 mL dose of PPV-23 intramuscularly once.
PPV-23: PPV-23 was a polysaccharide PNC vaccine, licensed in Brazil, directed against 23 serotypes.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2B (PCV-10)</title>
            <description>In Step 2, women who received Placebo in Step 1 and who were randomized to Arm 2B were administered a 0.5 mL dose of PCV-10 intramuscularly once.
PCV-10: PCV-10 was a conjugate PNC vaccine, licensed in Brazil, directed against 10 serotypes.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Women Who Experienced Grade ≥ 3 Adverse Events (AEs) in Step 2</title>
          <description>The number of women who enrolled in Step 2, received vaccine and who experience grade ≥ 3 adverse events (AEs) in the 4 weeks after vaccination in Step 2 is presented.</description>
          <population>Women who received Placebo in Step 1 and who were eligible and were randomized to Step 2.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 3+ AEs, up to week 4, Step 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3+ AEs related to treatment, Step 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>% with grade 3+ AEs, up to week 4 Step 2</param_type>
            <param_value>0</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0</ci_lower_limit>
            <ci_upper_limit>5</ci_upper_limit>
            <estimate_desc>Confidence intervals were Exact Clopper-Pearson.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>% with grade 3+ AEs, up to week 4 Step 2</param_type>
            <param_value>0</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0</ci_lower_limit>
            <ci_upper_limit>5</ci_upper_limit>
            <estimate_desc>Confidence intervals were Exact Clopper-Pearson.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Infants With Various Adverse Events Following Maternal Vaccination With PCV10 and PPV23 Administered in Pregnancy</title>
        <description>The number of infants who experience grade ≥ 3 adverse events (AEs), congenital defects, HIV infections or pneumonia, meningitis or IPD after maternal vaccination in Step 1, assessed from birth through 24 weeks of life for infant participants.</description>
        <time_frame>through 24 weeks of life for infant participants</time_frame>
        <population>Infants who were born on the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Infants Born to Women in Arm 1A (PPV-23)</title>
            <description>In Step 1, women in Arm 1A were administered a 0.5 milliliter (mL) dose of PPV-23 intramuscularly once.
PPV-23: PPV-23 was a polysaccharide PNC vaccine, licensed in Brazil, directed against 23 serotypes.</description>
          </group>
          <group group_id="O2">
            <title>Infants Born to Women in Arm 1B (PCV-10)</title>
            <description>In Step 1, women in Arm 1B were administered a 0.5 mL dose of PCV-10 intramuscularly once.
PCV-10: PCV-10 was a conjugate PNC vaccine, licensed in Brazil, directed against 10 serotypes.</description>
          </group>
          <group group_id="O3">
            <title>Infants Born to Women in Arm 1C (Placebo)</title>
            <description>In Step 1, women in Arm 1C were administered a 0.5 mL dose of 0.9 percent Sodium Chloride (NaCl) intramuscularly once.
NaCl: NaCl was the placebo for the study against which the two vaccines were compared during pregnancy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Infants With Various Adverse Events Following Maternal Vaccination With PCV10 and PPV23 Administered in Pregnancy</title>
          <description>The number of infants who experience grade ≥ 3 adverse events (AEs), congenital defects, HIV infections or pneumonia, meningitis or IPD after maternal vaccination in Step 1, assessed from birth through 24 weeks of life for infant participants.</description>
          <population>Infants who were born on the study.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="116"/>
                <count group_id="O3" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 3+ AEs,</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Congenital Anomalies</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HIV Infected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pneumonia, meningitis or IPD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>% infants with grade 3+ AEs</param_type>
            <param_value>21</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>14</ci_lower_limit>
            <ci_upper_limit>28</ci_upper_limit>
            <estimate_desc>Confidence intervals were Exact Clopper-Pearson.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>% infants with grade 3+ AEs</param_type>
            <param_value>20</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>14</ci_lower_limit>
            <ci_upper_limit>27</ci_upper_limit>
            <other_analysis_desc>Confidence intervals were Exact Clopper-Pearson.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>% infants with grade 3+ AEs</param_type>
            <param_value>20</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>14</ci_lower_limit>
            <ci_upper_limit>27</ci_upper_limit>
            <estimate_desc>Confidence intervals were Exact Clopper-Pearson.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>% infants with congenital anomalies</param_type>
            <param_value>17</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>11</ci_lower_limit>
            <ci_upper_limit>24</ci_upper_limit>
            <other_analysis_desc>Confidence intervals were Exact Clopper-Pearson.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>% infants with congenital anomalies</param_type>
            <param_value>22</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>15</ci_lower_limit>
            <ci_upper_limit>29</ci_upper_limit>
            <other_analysis_desc>Confidence intervals were Exact Clopper-Pearson.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>% infants with congenital anomalies</param_type>
            <param_value>13</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8</ci_lower_limit>
            <ci_upper_limit>19</ci_upper_limit>
            <estimate_desc>Confidence intervals were Exact Clopper-Pearson.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>% infants with HIV infection</param_type>
            <param_value>0</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0</ci_lower_limit>
            <ci_upper_limit>3</ci_upper_limit>
            <other_analysis_desc>Confidence intervals were Exact Clopper-Pearson.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>% infants with HIV infection</param_type>
            <param_value>0</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0</ci_lower_limit>
            <ci_upper_limit>3</ci_upper_limit>
            <estimate_desc>Confidence intervals were Exact Clopper-Pearson.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>% infants with HIV infection</param_type>
            <param_value>0</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0</ci_lower_limit>
            <ci_upper_limit>2</ci_upper_limit>
            <estimate_desc>Confidence intervals were Exact Clopper-Pearson.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>% with pneumonia, meningitis or IPD</param_type>
            <param_value>4</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2</ci_lower_limit>
            <ci_upper_limit>9</ci_upper_limit>
            <estimate_desc>Confidence intervals were Exact Clopper-Pearson.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>% with pneumonia, meningitis or IPD</param_type>
            <param_value>7</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3</ci_lower_limit>
            <ci_upper_limit>12</ci_upper_limit>
            <estimate_desc>Confidence intervals were Exact Clopper-Pearson.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>% with pneumonia, meningitis or IPD</param_type>
            <param_value>7</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3</ci_lower_limit>
            <ci_upper_limit>12</ci_upper_limit>
            <estimate_desc>Confidence intervals were Exact Clopper-Pearson.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Women With a Two-fold or Higher Increase in ELISA-measured IgG PNC Antibody Concentrations</title>
        <description>The number of participants with a two-fold or higher increase in ELISA-measured IgG PNC antibody concentrations from baseline to 28 days after immunization in Step 1 to 1 or more serotypes.
The proportion of participants with &gt;=0.35ug/mL ELISA-measured IgG PNC antibody concentrations at 28 days after immunization in Step 1 to 1 or more serotypes.</description>
        <time_frame>28 days after Immunization in Step 1</time_frame>
        <population>Pregnant women who received the vaccination and did not deliver prior to the day 28 study visit and who had ELISA-measured IgG PNC antibody concentrations measured at baseline and at 28 days after immunization.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1A (PPV-23)</title>
            <description>In Step 1, women in Arm 1A were administered a 0.5 milliliter (mL) dose of PPV-23 intramuscularly once.
PPV-23: PPV-23 was a polysaccharide PNC vaccine, licensed in Brazil, directed against 23 serotypes.</description>
          </group>
          <group group_id="O2">
            <title>Arm 1B (PCV-10)</title>
            <description>In Step 1, women in Arm 1B were administered a 0.5 mL dose of PCV-10 intramuscularly once.
PCV-10: PCV-10 was a conjugate PNC vaccine, licensed in Brazil, directed against 10 serotypes.</description>
          </group>
          <group group_id="O3">
            <title>Arm 1C (Placebo)</title>
            <description>In Step 1, women in Arm 1C were administered a 0.5 mL dose of 0.9 percent Sodium Chloride (NaCl) intramuscularly once.
NaCl: NaCl was the placebo for the study against which the two vaccines were compared during pregnancy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Women With a Two-fold or Higher Increase in ELISA-measured IgG PNC Antibody Concentrations</title>
          <description>The number of participants with a two-fold or higher increase in ELISA-measured IgG PNC antibody concentrations from baseline to 28 days after immunization in Step 1 to 1 or more serotypes.
The proportion of participants with &gt;=0.35ug/mL ELISA-measured IgG PNC antibody concentrations at 28 days after immunization in Step 1 to 1 or more serotypes.</description>
          <population>Pregnant women who received the vaccination and did not deliver prior to the day 28 study visit and who had ELISA-measured IgG PNC antibody concentrations measured at baseline and at 28 days after immunization.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="114"/>
                <count group_id="O3" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&gt;=2 fold change from baseline to day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106"/>
                    <measurement group_id="O2" value="112"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=0.35ug.mL at day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109"/>
                    <measurement group_id="O2" value="114"/>
                    <measurement group_id="O3" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>This is the test to compare the two vaccine arms with respect to proportion of participants with &gt;=2 fold increase at day 28.</non_inferiority_desc>
            <p_value>0.44</p_value>
            <p_value_desc>The threshold for statistical significance is 0.05.</p_value_desc>
            <method>Fisher Exact</method>
            <method_desc>Fisher's exact test was used because 50% of the cells had expected counts less than 5.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>This is the test to compare the two vaccine arms with respect to proportion of participants with values &gt;=0.35ug/mL at day 28.</non_inferiority_desc>
            <p_value>0.49</p_value>
            <p_value_desc>The threshold for statistical significance is 0.05.</p_value_desc>
            <method>Fisher Exact</method>
            <method_desc>Fisher's exact test was used because 50% of the cells had expected counts less than 5.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>% vaccinees with &gt;=2fold increase</param_type>
            <param_value>96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>91</ci_lower_limit>
            <ci_upper_limit>99</ci_upper_limit>
            <estimate_desc>Confidence intervals were Exact Clopper-Pearson.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>% vaccinees with &gt;=2fold increase</param_type>
            <param_value>98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>94</ci_lower_limit>
            <ci_upper_limit>100</ci_upper_limit>
            <estimate_desc>Confidence intervals were Exact Clopper-Pearson.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>% with &gt;=2 fold increase</param_type>
            <param_value>6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3</ci_lower_limit>
            <ci_upper_limit>12</ci_upper_limit>
            <estimate_desc>Confidence intervals were Exact Clopper-Pearson.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>% vaccinees with &gt;=0.35ug/mL at day 28</param_type>
            <param_value>99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>95</ci_lower_limit>
            <ci_upper_limit>100</ci_upper_limit>
            <estimate_desc>Confidence intervals were Exact Clopper-Pearson.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>% vaccinees with &gt;=0.35ug/mL at day 28</param_type>
            <param_value>100</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>97</ci_lower_limit>
            <ci_upper_limit>100</ci_upper_limit>
            <estimate_desc>Confidence intervals were Exact Clopper-Pearson.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>% with &gt;=0.35ug/mL at day 28</param_type>
            <param_value>94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>88</ci_lower_limit>
            <ci_upper_limit>97</ci_upper_limit>
            <estimate_desc>Confidence intervals were Exact Clopper-Pearson.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Infant Participants With ELISA-measured IgG PNC Antibody Levels ≥ 0.35ug/mL at 8 Weeks of Age</title>
        <description>The number of infant participants with ELISA-measured IgG PNC antibody levels ≥ 0.35ug/mL at 8 weeks of age to 1 or more serotypes.</description>
        <time_frame>8 Weeks of Life</time_frame>
        <population>The are the infants who were born on study and who had blood drawn for the week 8 evaluation prior to receiving their PCV-10 vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1A (PPV-23)</title>
            <description>These are the infants born to the pregnant women in Arm 1A. In Step 1, women in Arm 1A were administered a 0.5 milliliter (mL) dose of PPV-23 intramuscularly once.
PPV-23: PPV-23 was a polysaccharide PNC vaccine, licensed in Brazil, directed against 23 serotypes.</description>
          </group>
          <group group_id="O2">
            <title>Arm 1B (PCV-10)</title>
            <description>These are the infants born to the pregnant women in Arm 1B. In Step 1, women in Arm 1B were administered a 0.5 mL dose of PCV-10 intramuscularly once.
PCV-10: PCV-10 was a conjugate PNC vaccine, licensed in Brazil, directed against 10 serotypes.</description>
          </group>
          <group group_id="O3">
            <title>Arm 1C (Placebo)</title>
            <description>These are the infants born to women enrolled in Arm 1C. In Step 1, women in Arm 1C were administered a 0.5 mL dose of 0.9 percent Sodium Chloride (NaCl) intramuscularly once.
NaCl: NaCl was the placebo for the study against which the two vaccines were compared during pregnancy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Infant Participants With ELISA-measured IgG PNC Antibody Levels ≥ 0.35ug/mL at 8 Weeks of Age</title>
          <description>The number of infant participants with ELISA-measured IgG PNC antibody levels ≥ 0.35ug/mL at 8 weeks of age to 1 or more serotypes.</description>
          <population>The are the infants who were born on study and who had blood drawn for the week 8 evaluation prior to receiving their PCV-10 vaccination.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="95"/>
                    <measurement group_id="O3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.29</p_value>
            <p_value_desc>The threshold for statistical significance is 0.05.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ratio of Infant/Mother PNC Antibody Levels</title>
        <description>The ratios of infant/mother PNC antibody levels to study used serotypes.</description>
        <time_frame>At Delivery for Mother Participants and Birth for Infant Participants</time_frame>
        <population>These are the mother-infant pairs who meet the criteria of receipt of study product for the moms and have data for delivery/birth time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1A (PPV-23)</title>
            <description>In Step 1, women in Arm 1A were administered a 0.5 milliliter (mL) dose of PPV-23 intramuscularly once.
PPV-23: PPV-23 was a polysaccharide PNC vaccine, licensed in Brazil, directed against 23 serotypes.</description>
          </group>
          <group group_id="O2">
            <title>Arm 1B (PCV-10)</title>
            <description>In Step 1, women in Arm 1B were administered a 0.5 mL dose of PCV-10 intramuscularly once.
PCV-10: PCV-10 was a conjugate PNC vaccine, licensed in Brazil, directed against 10 serotypes.</description>
          </group>
          <group group_id="O3">
            <title>Arm 1C (Placebo)</title>
            <description>In Step 1, women in Arm 1C were administered a 0.5 mL dose of 0.9 percent Sodium Chloride (NaCl) intramuscularly once.
NaCl: NaCl was the placebo for the study against which the two vaccines were compared during pregnancy.</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio of Infant/Mother PNC Antibody Levels</title>
          <description>The ratios of infant/mother PNC antibody levels to study used serotypes.</description>
          <population>These are the mother-infant pairs who meet the criteria of receipt of study product for the moms and have data for delivery/birth time point.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.92" lower_limit="0.91" upper_limit="0.93"/>
                    <measurement group_id="O2" value="0.93" lower_limit="0.92" upper_limit="0.94"/>
                    <measurement group_id="O3" value="0.90" lower_limit="0.89" upper_limit="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.08</p_value>
            <p_value_desc>The threshold for statistical significance is 0.05.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a &gt;=0.35ug/mL ELISA-measured IgG PNC Antibody Concentrations at Labor/Delivery and 24 Weeks Post-partum</title>
        <description>The number of participants with a &gt;=0.35ug/mL ELISA-measured IgG PNC antibody concentrations at the time points listed for 1 or more serotypes.</description>
        <time_frame>at Labor and Delivery and 24 Weeks Post-Delivery for Mother Participants</time_frame>
        <population>Pregnant women who received the vaccination and did not deliver prior to the day 28 study visit and who had ELISA-measured IgG PNC antibody concentrations measured at the timepoints listed.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1A (PPV-23)</title>
            <description>In Step 1, women in Arm 1A were administered a 0.5 milliliter (mL) dose of PPV-23 intramuscularly once.
PPV-23: PPV-23 was a polysaccharide PNC vaccine, licensed in Brazil, directed against 23 serotypes.</description>
          </group>
          <group group_id="O2">
            <title>Arm 1B (PCV-10)</title>
            <description>In Step 1, women in Arm 1B were administered a 0.5 mL dose of PCV-10 intramuscularly once.
PCV-10: PCV-10 was a conjugate PNC vaccine, licensed in Brazil, directed against 10 serotypes.</description>
          </group>
          <group group_id="O3">
            <title>Arm 1C (Placebo)</title>
            <description>In Step 1, women in Arm 1C were administered a 0.5 mL dose of 0.9 percent Sodium Chloride (NaCl) intramuscularly once.
NaCl: NaCl was the placebo for the study against which the two vaccines were compared during pregnancy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a &gt;=0.35ug/mL ELISA-measured IgG PNC Antibody Concentrations at Labor/Delivery and 24 Weeks Post-partum</title>
          <description>The number of participants with a &gt;=0.35ug/mL ELISA-measured IgG PNC antibody concentrations at the time points listed for 1 or more serotypes.</description>
          <population>Pregnant women who received the vaccination and did not deliver prior to the day 28 study visit and who had ELISA-measured IgG PNC antibody concentrations measured at the timepoints listed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="115"/>
                <count group_id="O3" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>at labor and delivery</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="113"/>
                    <count group_id="O2" value="115"/>
                    <count group_id="O3" value="116"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109"/>
                    <measurement group_id="O2" value="115"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at 24 weeks post partum</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="107"/>
                    <count group_id="O2" value="108"/>
                    <count group_id="O3" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="107"/>
                    <measurement group_id="O3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>This is the test to compare the two vaccine arms with respect to proportion of participants with &gt;=2 fold increase at labor and delivery.</non_inferiority_desc>
            <p_value>0.37</p_value>
            <p_value_desc>The threshold for statistical significance is 0.05.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>This is the test to compare the two vaccine arms with respect to proportion of participants with &gt;=2 fold increase at 24 weeks post partum.</non_inferiority_desc>
            <p_value>0.21</p_value>
            <method>Fisher Exact</method>
            <method_desc>Fisher's exact test was used because 50% of the cells had expected counts less than 5.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Two-fold or Higher Increase in ELISA-measured IgG PNC Antibody Concentrations at 28 Days After PPV-23 Vaccination in Step 1 and Step 2</title>
        <description>The number of participants with a two-fold or higher increase in ELISA-measured IgG PNC antibody concentrations from baseline to 28 days after immunization in Step 1 vs from entry to Step 2 to 28 days after immunization in Step 2 to 1 or more serotypes.</description>
        <time_frame>28 days after Immunization in Step 1 and in Step 2</time_frame>
        <population>Women who received PPV-23 in Step 1 or in Step 2 and who had ELISA-measured IgG PNC antibody concentrations data.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1A (PPV-23)</title>
            <description>In Step 1, women in Arm 1A were administered a 0.5 milliliter (mL) dose of PPV-23 intramuscularly once.
PPV-23: PPV-23 was a polysaccharide PNC vaccine, licensed in Brazil, directed against 23 serotypes.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2A (PPV-23)</title>
            <description>In Step 2, women who received placebo in step 1 that were randomized to Arm 2A were administered a 0.5 mL dose of PPV-23 intramuscularly once.
PPV-23: PPV-23 was a polysaccharide PNC vaccine, licensed in Brazil, directed against 23 serotypes.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Two-fold or Higher Increase in ELISA-measured IgG PNC Antibody Concentrations at 28 Days After PPV-23 Vaccination in Step 1 and Step 2</title>
          <description>The number of participants with a two-fold or higher increase in ELISA-measured IgG PNC antibody concentrations from baseline to 28 days after immunization in Step 1 vs from entry to Step 2 to 28 days after immunization in Step 2 to 1 or more serotypes.</description>
          <population>Women who received PPV-23 in Step 1 or in Step 2 and who had ELISA-measured IgG PNC antibody concentrations data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106"/>
                    <measurement group_id="O2" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>% vaccinees with &gt;=2fold increase</param_type>
            <param_value>96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>91</ci_lower_limit>
            <ci_upper_limit>99</ci_upper_limit>
            <estimate_desc>Confidence intervals were Exact Clopper-Pearson.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>% vaccinees with &gt;=2fold increase</param_type>
            <param_value>98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>89</ci_lower_limit>
            <ci_upper_limit>100</ci_upper_limit>
            <estimate_desc>Confidence intervals were Exact Clopper-Pearson.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Two-fold or Higher Increase in ELISA-measured IgG PNC Antibody Concentrations at 28 Days After PCV-10 Vaccination in Step 1 and Step 2</title>
        <description>The proportion of participants with a two-fold or higher increase in ELISA-measured IgG PNC antibody concentrations from baseline to 28 days after immunization in Step 1 vs from entry to Step 2 to 28 days after immunization in Step 2 to 1 or more serotypes.</description>
        <time_frame>28 days after Immunization in Step 1 and in Step 2</time_frame>
        <population>Women who received PCV-10 in Step 1 or in Step 2 and who had ELISA-measured IgG PNC antibody concentrations data.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1B (PCV-10)</title>
            <description>In Step 1, women in Arm 1B were administered a 0.5 mL dose of PCV-10 intramuscularly once.
PCV-10: PCV-10 was a conjugate PNC vaccine, licensed in Brazil, directed against 10 serotypes.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2B (PCV-10)</title>
            <description>In Step 2, women who received Placebo in Step 1 and who were randomized to Arm 2B were administered a 0.5 mL dose of PCV-10 intramuscularly once.
PCV-10: PCV-10 was a conjugate PNC vaccine, licensed in Brazil, directed against 10 serotypes.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Two-fold or Higher Increase in ELISA-measured IgG PNC Antibody Concentrations at 28 Days After PCV-10 Vaccination in Step 1 and Step 2</title>
          <description>The proportion of participants with a two-fold or higher increase in ELISA-measured IgG PNC antibody concentrations from baseline to 28 days after immunization in Step 1 vs from entry to Step 2 to 28 days after immunization in Step 2 to 1 or more serotypes.</description>
          <population>Women who received PCV-10 in Step 1 or in Step 2 and who had ELISA-measured IgG PNC antibody concentrations data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>% vaccinees with &gt;=2fold increase</param_type>
            <param_value>98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>94</ci_lower_limit>
            <ci_upper_limit>100</ci_upper_limit>
            <other_analysis_desc>Confidence intervals were Exact Clopper-Pearson.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>% vaccinees with &gt;=2fold increase</param_type>
            <param_value>100</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>93</ci_lower_limit>
            <ci_upper_limit>100</ci_upper_limit>
            <estimate_desc>Confidence intervals were Exact Clopper-Pearson.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Infant Participants With ELISA-measured IgG PNC Antibody Levels ≥ 0.35ug/mL at 16 and 24 Weeks of Age</title>
        <description>The number of infant participants with ELISA-measured IgG PNC antibody levels ≥ 0.35ug/mL at 16 and 24 weeks of age to 1 or more serotypes.</description>
        <time_frame>at weeks 16 and 24 of life</time_frame>
        <population>These are the infants who were born on study and received the PCV-10 vaccination in the windows allowed by the protocol (prior to week 8 and prior to week 16). The number of infants with nonmissing data who received the vaccination as required are indicated.</population>
        <group_list>
          <group group_id="O1">
            <title>Infants of Mothers in Arm 1A (PPV-23)</title>
            <description>These are the infants born to women enrolled in Arm 1A. In Step 1, women in Arm 1A were administered a 0.5 milliliter (mL) dose of PPV-23 intramuscularly once.
PPV-23: PPV-23 was a polysaccharide PNC vaccine, licensed in Brazil, directed against 23 serotypes.</description>
          </group>
          <group group_id="O2">
            <title>Infants of Mothers in Arm 1B (PCV-10)</title>
            <description>These are the infants born to women enrolled in Arm 1B. In Step 1, women in Arm 1B were administered a 0.5 mL dose of PCV-10 intramuscularly once.
PCV-10: PCV-10 was a conjugate PNC vaccine, licensed in Brazil, directed against 10 serotypes.</description>
          </group>
          <group group_id="O3">
            <title>Infants of Mothers in Arm 1C (Placebo)</title>
            <description>These are the infants born to women enrolled in Arm 1C. In Step 1, women in Arm 1C were administered a 0.5 mL dose of 0.9 percent Sodium Chloride (NaCl) intramuscularly once.
NaCl: NaCl was the placebo for the study against which the two vaccines were compared during pregnancy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Infant Participants With ELISA-measured IgG PNC Antibody Levels ≥ 0.35ug/mL at 16 and 24 Weeks of Age</title>
          <description>The number of infant participants with ELISA-measured IgG PNC antibody levels ≥ 0.35ug/mL at 16 and 24 weeks of age to 1 or more serotypes.</description>
          <population>These are the infants who were born on study and received the PCV-10 vaccination in the windows allowed by the protocol (prior to week 8 and prior to week 16). The number of infants with nonmissing data who received the vaccination as required are indicated.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>at week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="100"/>
                    <count group_id="O2" value="96"/>
                    <count group_id="O3" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="94"/>
                    <measurement group_id="O3" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="102"/>
                    <count group_id="O2" value="99"/>
                    <count group_id="O3" value="99"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                    <measurement group_id="O2" value="98"/>
                    <measurement group_id="O3" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>% infants with &gt;=0.35ug/mL at week 16</param_type>
            <param_value>100</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>96</ci_lower_limit>
            <ci_upper_limit>100</ci_upper_limit>
            <estimate_desc>Confidence intervals were Exact Clopper-Pearson.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>% infants with &gt;=0.35ug/mL at week 16</param_type>
            <param_value>98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>93</ci_lower_limit>
            <ci_upper_limit>100</ci_upper_limit>
            <estimate_desc>Confidence intervals were Exact Clopper-Pearson.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>% infants with &gt;=0.35ug/mL at week 16</param_type>
            <param_value>97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>91</ci_lower_limit>
            <ci_upper_limit>99</ci_upper_limit>
            <other_analysis_desc>Confidence intervals were Exact Clopper-Pearson.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>% infants with &gt;=0.35ug/mL at week 24</param_type>
            <param_value>100</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>96</ci_lower_limit>
            <ci_upper_limit>100</ci_upper_limit>
            <estimate_desc>Confidence intervals were Exact Clopper-Pearson.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>% infants with &gt;=0.35ug/mL at week 24</param_type>
            <param_value>99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>95</ci_lower_limit>
            <ci_upper_limit>100</ci_upper_limit>
            <estimate_desc>Confidence intervals were Exact Clopper-Pearson.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>% infants with &gt;=0.35ug/mL at week 24</param_type>
            <param_value>98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>93</ci_lower_limit>
            <ci_upper_limit>100</ci_upper_limit>
            <estimate_desc>Confidence intervals were Exact Clopper-Pearson.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>For women: up to 28 weeks post-delivery (24 weeks +4 week window) for Steps 1A, 1B, 1C or those who continued to Step 3 (no additional safety follow-up was performed in Step 3); 4 weeks for Steps 2A and 2B; and up to 28 weeks for infants (24 weeks +4 week window).</time_frame>
      <desc>For women: all grade &gt;=2 signs/symptoms and diagnoses, and all hematology (CBC with differential and platelet count) adverse events. AEs collected for infants: infant death, congenital anomalies, prematurity, low birth weight, neonatal infections/sepsis, Neonatal Intensive Care Unit (NICU) admission, HIV transmission to infant, functional defects (hearing impairment, growth impairment, developmental delay) and Grade ≥ 3 AEs. SAEs were reported according to DAIDS EAE Manual V2.0 (see References).</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm 1A (PPV-23)</title>
          <description>In Step 1, women in Arm 1A were administered a 0.5 milliliter (mL) dose of PPV-23 intramuscularly once.
PPV-23: PPV-23 was a polysaccharide PNC vaccine, licensed in Brazil, directed against 23 serotypes.</description>
        </group>
        <group group_id="E2">
          <title>Arm 1B (PCV-10)</title>
          <description>In Step 1, women in Arm 1B were administered a 0.5 mL dose of PCV-10 intramuscularly once.
PCV-10: PCV-10 was a conjugate PNC vaccine, licensed in Brazil, directed against 10 serotypes.</description>
        </group>
        <group group_id="E3">
          <title>Arm 1C (Placebo)</title>
          <description>In Step 1, women in Arm 1C were administered a 0.5 mL dose of 0.9 percent Sodium Chloride (NaCl) intramuscularly once.
NaCl: NaCl was the placebo for the study against which the two vaccines were compared during pregnancy.</description>
        </group>
        <group group_id="E4">
          <title>Arm 2A (PPV-23)</title>
          <description>In Step 2, women in Arm 2A were administered a 0.5 milliliter (mL) dose of PPV-23 intramuscularly once.
PPV-23: PPV-23 was a polysaccharide PNC vaccine, licensed in Brazil, directed against 23 serotypes.</description>
        </group>
        <group group_id="E5">
          <title>Arm 2B (PCV-10)</title>
          <description>In Step 2, women in Arm 2B were administered a 0.5 mL dose of PCV-10 intramuscularly once.
PCV-10: PCV-10 was a conjugate PNC vaccine, licensed in Brazil, directed against 10 serotypes.</description>
        </group>
        <group group_id="E6">
          <title>Infants of Mothers in Arm 1A (PPV-23)</title>
          <description>These are the infants born to women enrolled in Arm 1A. In Step 1, women in Arm 1A were administered a 0.5 milliliter (mL) dose of PPV-23 intramuscularly once.
PPV-23: PPV-23 was a polysaccharide PNC vaccine, licensed in Brazil, directed against 23 serotypes.</description>
        </group>
        <group group_id="E7">
          <title>Infants of Mothers in Arm 1B (PCV-10)</title>
          <description>These are the infants born to women enrolled in Arm 1B. In Step 1, women in Arm 1B were administered a 0.5 mL dose of PCV-10 intramuscularly once.
PCV-10: PCV-10 was a conjugate PNC vaccine, licensed in Brazil, directed against 10 serotypes.</description>
        </group>
        <group group_id="E8">
          <title>Infants of Mothers in Arm 1C (Placebo)</title>
          <description>These are the infants born to women enrolled in Arm 1C. In Step 1, women in Arm 1C were administered a 0.5 mL dose of 0.9 percent Sodium Chloride (NaCl) intramuscularly once.
NaCl: NaCl was the placebo for the study against which the two vaccines were compared during pregnancy.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 22</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="20" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="21" subjects_at_risk="116"/>
                <counts group_id="E8" subjects_affected="19" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital diaphragmatic hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Congenital hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Congenital syphilis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="116"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Pancreatic mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever neonatal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Endometritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Pulmonary sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Uterine infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Incision site infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="116"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Neurosyphilis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="116"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Sepsis neonatal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="116"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Post lumbar puncture syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Anogenital warts</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Eclampsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Foetal distress syndrom</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Oligohydramnios</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Postpartum haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Pre-eclampsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Premature labour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Threatened labour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Gestational hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Preterm premature rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Jaundice neonatal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Premature baby</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Foetal growth restriction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Neonatal asphyxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Neonatal respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Respiratory depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Tachypnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Transient tachypnoea of newborn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="116"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Neonatal hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis bullous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 22</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="62" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="115"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="117"/>
                <counts group_id="E8" subjects_affected="17" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="115"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="117"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Vulvovaginal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal discharge</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="115"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="117"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="115"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lauren Laimon, Senior Study Director</name_or_title>
      <organization>Westat</organization>
      <phone>240-453-2987</phone>
      <email>LaurenLaimon@westat.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

